The most common side effect that causes drug discontinuation in patients with type 2 diabetes taking GLP-1 RAs is gastrointestinal intolerance. One study noted an increased risk for gallstones or biliary tract-related events with the use of GLP-1 RAs.
GLP-1 RAs are available in oral and injectable formulations.
An increased risk for genital fungal infections and urinary tract infections has been observed with SGLT2 inhibitors; however, most are easily managed. Urinary tract infections have not been observed with the use of DPP-4 inhibitors.
Learn more about type 2 diabetes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori, Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy - Medscape - May 16, 2022.